This study will explore potential links between atopic dermatitis and food allergy to determine unique biochemical or genetic identifiers useful for diagnosing and treatments in the future.

Eligible Participants

• Age 10-55 years
• Current diagnosis of food allergy with a history of food anaphylaxis and/or Current diagnosis of Atopic dermatitis

For more information, visit U-M Health Research Study page 

Sponsor: Private donor, NIH
PI: Charles Schuler IV, MD
Current Status: Enrolling

This clinical research study will investigate the safety and effect of a peanut immunotherapy tablet in adults, teenagers and children with a peanut allergy. 

Eligible Participants

• Age 4-17 years (adult recruitment has closed)
• History of diagnosed peanut allergy

For more information, visit U-M Health Research study page

Sponsor: ALK
PI: Ian Slack, MD
Current Status: Enrolling

A study to identify biomarkers and investigate mechanisms of food anaphylaxis. An observational and bio-sampling study of patients undergoing oral food challenges during routine clinical care or on research protocols for clinical trials.

Eligible Participants

Patients of University of Michigan Allergy undergoing a clinical oral food challenge

Sponsor: M-FARA, FARE Discovery Center of Distinction award, NIH/NIAID K23
PI: Charles Schuler IV, MD

The purpose of this study is to certify that an extensively broken-down milk protein based infant formula is hypoallergenic (designed to reduce or minimize the possibility of an allergic reaction) in infants and children with a confirmed cow’s milk allergy (CMA) according to the standards published by the American Academy of Pediatrics (AAP). 

Sponsor: Abbott
PI: Ian Slack, MD
Current Status: Upcoming

This study is evaluating multifood oral immunotherapy as a treatment for food allergy. A phase 1/2 clinical trial evaluating an oral formulation of 15 individual food sources (ADP101) that are responsible for approximately 90% of food allergies in the United States to be used as an oral immunotherapy (OIT) for the mitigation of allergic reactions. The study has now transitioned to ENCORE Study (open-label extension study) to investigate long-term safety, tolerability, and efficacy of orally administered ADP101.

Sponsor: Alladapt
PI: Ian Slack, MD
Current Status: Ongoing (closed to enrollment)

A phase 3 clinical trial to assess the clinical benefit of Viaskin Peanut patch and evaluate safety of long-term treatment of epicutaneous immunotherapy to induce/maintain desensitization to peanut in peanut-allergic children.   

Sponsor: DBV Technologies
PI: Kelly O’Shea, MD
Current Status: Ongoing (closed to enrollment)

This study will investigate water loss across the skin as a marker for severe allergic reactions during oral food challenges.  An observational study to evaluate a noninvasive biomarker, transepidermal water loss (TEWL), during oral food challenges to predict anaphylaxis before it is otherwise clinically apparent.

Sponsor: Gerber Foundation
PI: Charles Schuler IV, MD
Current Status: Undergoing data analysis

This study is evaluating whether a daily probiotic by mouth can prevent the development of allergies. A phase 1b/2 study to evaluate the safety and efficacy of a probiotic (STMC-103H) in neonates and infants to prevent the development of allergic disease. 

Sponsor: Siolta Therapeutics
PI: Georgiana Sanders, MD
Current Status: Ongoing (closed to enrollment)

This study is testing a new injectable drug for food allergy. A phase 3 clinical trial to evaluate the safety and clinical efficacy of ligelizumab (anti-IgE) on peanut reaction threshold in peanut-allergic individuals.

Sponsor: Novartis
PI: Georgiana Sanders, MD
Current Status: Ongoing (closed to enrollment)

The purpose of the study is to assess if remibrutinib can provide protection against allergic reactions to increasing doses of peanut protein as measured by oral food challenge. 

Sponsor: Novartis
PI: Kelly O’Shea, MD
Current Status: Ongoing (closed to enrollment)